- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome | 221 | Business Wire | The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down... ► Artikel lesen | |
| 26.09. | Aelis Farma: Availability of the 2024 Half-year Financial Report | 195 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
| 25.09. | Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update | 268 | Business Wire | A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently... ► Artikel lesen | |
| 04.09. | Indivior reports "disappointing" results for study with Aelis Farma | 6 | Alliance News | ||
| 04.09. | Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder | 363 | PR Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN... ► Artikel lesen | |
| 04.09. | Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD) | 320 | Business Wire | The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies.... ► Artikel lesen | |
| 31.07. | Aelis Farma Announces the Successful Completion of Its Reserved Offering for a Total Gross Amount of €4.5 Million | 384 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS the "Company"), a... ► Artikel lesen | |
| 30.07. | Aelis Farma: Launch of a Reserved Offering of Approximately €5 Million | 418 | Business Wire | NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Launch of a Reserved Offering of new shares for c. €5 million aimed at categories... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 24.06. | Aelis Farma: Availability of the Description of the Share Buyback Program | 237 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces... ► Artikel lesen | |
| 04.06. | Results of Aelis Farma Combined General Meeting of June 4, 2024 | 325 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all... ► Artikel lesen | |
| 14.05. | Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures | 385 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders... ► Artikel lesen | |
| 25.04. | Aelis Farma: Availability of the 2023 Universal Registration Document | 272 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication... ► Artikel lesen | |
| 18.04. | Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder | 298 | Business Wire | The last patient in the clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder has completed its last medical visit, paving the way for the release of study results in... ► Artikel lesen | |
| 02.04. | Aelis Farma Reports Its 2023 Annual Financial Results and Confirms Its 2024 Outlook | 387 | Business Wire | 2023 has been marked by key milestones for the Company's two drug candidates: AEF0117: completion of patient recruitment for the phase 2b study with 333 patients in excessive cannabis... ► Artikel lesen | |
| 30.01. | Aelis Farma Announces Its 2024 Financial Calendar | 466 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its... ► Artikel lesen | |
| 17.01. | Aelis Farma Strengthens its Leadership Team with the Appointment of Arsène Guekam as Chief Corporate Development Officer | 538 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain disorders, today... ► Artikel lesen | |
| 09.01. | Aelis Farma Announces Completion of Patient Randomization for Phase 2b Study with AEF0117 for the Treatment of Cannabis Addiction | 549 | Business Wire | As planned, 333 patients have been randomized at end of December 2023 across 11 clinical centers in the United States This major milestone confirms the announced availability of the first... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,130 | +3,32 % | Neue 6,00% Aktienanleihe mit Barriere auf QIAGEN in Zeichnung | München (www.anleihencheck.de) - Die Experten vom Zertifikate-Team der Bank Vontobel Europe AG bieten eine neue Aktienanleihe (ISIN DE000VC7RDU1/ WKN VC7RDU) mit Barriere auf die Aktie von QIAGEN (ISIN... ► Artikel lesen | |
| EVOTEC | 9,845 | -0,61 % | Evotec: Extreme Ausschläge | Größer könnten die Gegensätze wohl kaum sein. Die Aktie von Evotec hat im zurückliegenden Jahren einen massiven Einbruch erfahren. Auf 52-Wochen-Sicht gehört sie zu den schlechtesten Aktien im SDAX.... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,660 | 0,00 % | Aktie von Relay Therapeutics erreicht 52-Wochen-Tief bei 5,59 US-Dollar | ||
| CULLINAN THERAPEUTICS | 12,580 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024 | Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global Phase... ► Artikel lesen | |
| GALAPAGOS NV | 24,100 | +0,25 % | GALAPAGOS NV - S-8, Securities to be offered to employees in employee benefit plans | ||
| VERVE THERAPEUTICS | 4,550 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| BIONTECH | 97,40 | -0,20 % | KURSEXPLOSION bei Biotech-Aktie! BioNTech, Evotec, Nyxoah | Geht es bei Evotec jetzt doch ganz schnell? Ein Finanzinvestor positioniert sich jedenfalls für eine Übernahme und die Aktie schoss zuletzt kräftig nach oben. Ist damit die Enttäuschung über die Quartalszahlen... ► Artikel lesen | |
| TECTONIC THERAPEUTIC | 44,030 | 0,00 % | Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein | Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 13,540 | 0,00 % | James E. Flynn Sells 528,456 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock | ||
| RECURSION PHARMACEUTICALS | 5,870 | -2,81 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| GUBRA | 81,60 | 0,00 % | AKTIONÄR-Depotwert Gubra: Die Katze ist aus dem Sack! | Am Mittwoch nach Börsenschluss in Kopenhagen hat der Wirkstoffforscher Gubra erste Phase-1-Daten zu seinem Adipositas-Hoffnungsträger GUBamy vorgelegt. Diese sind äußerst vielversprechend und sollten... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 13,695 | -3,62 % | Eckert & Ziegler: Top-Deal mit Telix Pharma - die Details! | Der Radiopharma-Markt ist und bleibt mächtig in Bewegung. Das unterfüttert ein neuer Kooperations- und Lizenzvertrag, den der deutsche Player Eckert & Ziegler mit dem australischen Radiopharma-Überflieger... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 8,715 | 0,00 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| BB BIOTECH | 38,400 | -0,65 % | BB Biotech Erkenntnisse beim Lunch mit Vorständen | Ich war wie versprochen beim Investorenlunch von BB Biotech. Der scheidende Vorstandssprecher Dr. Daniel Koller führte seinen Nachfolger Dr. Christian Koch ein. Wie jedes Jahr hielt Vorstandssprecher... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 43,860 | +0,46 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights | Enrollment in global Phase 3 HARBOR study for del-desiran in DM1 is on track
Avidity initiated biomarker cohort for del-brax FORTITUDE study for FSHD; pursuing a... ► Artikel lesen |
AELIS FARMA SAS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,160 (+5,80 %) liegt der Kurs bei 2,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.
